Early Results of the CellCept Spare the Nephron Study Examine
SAN FRANCISCO, May 07, 2007 /PRNewswire/ -- Interim results from
a multicenter trial investigating a novel kidney-sparing treatment
protocol using CellCept(R) (mycophenolate mofetil) were presented
at the American Transplant Congress. This and other Spare the
Nephron (STN) trials in kidney and liv...
Aspreva and Roche Announce Preliminary Results for Phase III Study
Evaluating CellCept in Lupus Nephritis
VICTORIA, BC, Canada and BASEL, Switzerland, June 27 /CNW/ -
Aspreva Pharmaceuticals Corporation (NASDAQ: ASPV; TSX: ASV) and
Roche today released preliminary results for a clinical trial
(oral mycophenolate mofetil, MMF) to intravenous
cyclophosphamide (IVC), which is the curren...
Lupus Foundation of America Statement on Results for Clinical Study
of CellCept Released by Aspreva Pharmaceutical Company
Statement by Sandra C. Raymond, President & CEO of the Lupus
Foundation of America, Inc.
WASHINGTON, June 27, 2007 /PRNewswire-USNewswire/ -- The Lupus
Foundation of America, Inc. and more than 1.5 million Americans
with lupus have been awaiting the preliminary findings of the Phase
CellCept(R) and a Reduced Level of CNI Shows Trend Towards Preservation of Kidney Function Versus a Standard-Dose CNI
... level of CNI with a therapeutic monitored dose of cellcept
inferior to that of a fixed dose of CellCep...hronic administration of CNI, facilitated a higher cellcept
an overall increase in adverse even...ients administered
either concentration-controlled cellcept
and a reduced level of CNI, a
Final Results of the CellCept(R) Spare the Nephron (STN) Study Show Maintenance Therapy is Associated with Improved Renal Function
...earson. "The STN Kidney
studied the combination of cellcept
and SRL with the goal of reducing CNI
associated n...up. Safety outcomes were similar in both groups.
is indicated for the prophylaxis of organ rejectio...ion.
Physicians should inform female patients that cellcept
use during pregnancy
is associated with increased ...
Organ Donor Shortage Remains Obstacle for Would-Be Transplant Patients Despite Better Medicine
...ch prevent the immune system from
rejecting a new organ, may have become victims of their own success.
Medicines such as Astella's Prograf and Roche's cellcept
incidence of acute organ rejection and made transplantation a viable option
in more cases, thus increased organ waiting lists. Kidney acu...